Gilead Sciences Inc 

GILD:NASDAQ

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
53.33 0.00   0.00%0.00%12,07713.8M

Market data is delayed by at least 20 minutes.
Previous close 4/23/2013
 
 
 

Latest News Headlines for Gilead Sciences Inc

Gilead Sciences Supports HarborPath's HIV/AIDS Medication Assistance Pilot Program
10 minutes ago - Pr Newswire
HarborPath, an organization which provides a single point of access to HIV/AIDS medications through patient assistance programs, welcomes Gilead Sciences as a participating company. Gilead joins Merck and ViiV Healthcare as the third pharmaceutical company to support HarborPath since its launch in July 2012.
Data from Phase 3 studies of Gilead's sofosbuvir for hepatitis C to be presented at 48th Annual EASL Meeting; Findings published online today in The New England Journal of Medicine
20 hours 53 minutes ago - Cnw Group
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus (HCV) infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver (International Liver Congress 2013) in Amsterdam, The Netherlands. In addition, detailed results from the four clinical studies have also been published online in two papers, ahead of print, in The New England Journal of Medicine (NEJM).
Gilead Sciences (GILD) Crosses Pivot Point Resistance at $54.43
22 hours 45 minutes ago - Financial News Network Online - Pivot Alerts
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $53.86 and have already reached the first level of resistance at $54.43. Should the shares continue to rise, the resistance pivots of $54.81 and $55.76 will be of interest.
View more recent headlines
 
 
 
 
 
 
More Filings

Latest Annual and Quarterly SEC Filings

10-K
February 27, 2013
This report contains detailed information about the company's business finances and management.
10-Q
November 6, 2012
Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)
 
 
 
Company Background
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company's products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.

Bid/Size
-- / --
Ask/Size
-- / --
Price Open
0.00
Previous Close
53.33
Day High
0.00
Day Low
0.00
52wk High/Date
55.16 / 4/23/2013
52wk Low/Date
24.12 / 6/5/2012
% off 52wk High
-3.32%
% off 52wk Low
121.10%
Beta (5 Yr)
0.5
Market Capitalization
81.3B
Shares Outstanding
1.5B
Volatility Avg
27.83
EPS(TTM)
1.36
P/E Ratio
39.3x
Dividend Announcement
--
Dividend Yield
0.00%
Ex-Date
--
Date of Record
--
Payable
0.00 - --
Payable Date
--
Last Trade as of 4/23/2013 4:00 PM ET
 
 
 

GILD Gilead Sciences Inc vs. Peers

Peers 
GILD
Gilead Sciences Inc
45.21%
Abbott Laboratories
18.73%
Merck & Co., Inc.
18.78%
Pfizer Inc.
23.93%
GILD
Gilead Sciences Inc
0.00%
Abbott Laboratories
1.50%
Merck & Co., Inc.
3.54%
Pfizer Inc.
3.09%
GILD
Gilead Sciences Inc
0.00%
Abbott Laboratories
0.00%
Merck & Co., Inc.
0.00%
Pfizer Inc.
0.00%
Compare these stocks